Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trialsMeta-Analysis Published on 2022-04-012023-07-07 Journal: Expert review of anti-infective therapy [Category] COVID19(2023년), [키워드] antivirals COVID-19 Mortality SARS-CoV-2 severity sofosbuvir [DOI] 10.1080/14787210.2022.2000861 [Article Type] Meta-Analysis
Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trialsSofosbuvir 기반 치료가 COVID-19 환자의 임상 결과에 미치는 영향: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-03-012022-09-11 Journal: International journal of antimicrobial agents [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] 95% CI 95% confidence interval Admission Antiviral Antiviral treatment Clinical efficacy Clinical outcome clinical outcomes clinical recovery ClinicalTrials comparator control group Controlled controlled trials coronavirus disease Coronavirus disease 2019 COVID-19 deviation Effect Efficacy examined exhibited help hospital ICU IMPROVE inception intensive care intensive care unit admission mean deviation mechanical ventilation Meta-analysis Mortality Odds ratio Patient patients with COVID-19 randomised controlled trial Recovery time reduce mortality regimen Safe SARS-CoV-2 searched sofosbuvir Standard of care study group systematic review the study group Treatment [DOI] 10.1016/j.ijantimicag.2022.106545 PMC 바로가기 [Article Type] Meta-Analysis
High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infectionArticle Published on 2022-03-012023-06-11 Journal: Antiviral Research [Category] E형 간염, [키워드] combination therapy hepatitis E virus ribavirin sofosbuvir [DOI] 10.1016/j.antiviral.2022.105274
Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage unitsArticle Published on 2022-02-152023-07-07 Journal: Spectrochimica acta. Part A, Molecular and biomole [Category] COVID19(2023년), [키워드] COVID 19 Derivative/zero ratio spectrophotometry First derivative spectrophotometry HCV ledipasvir sofosbuvir [DOI] 10.1016/j.saa.2021.120623
Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian studyRandomized Controlled Trial Published on 2022-02-012023-07-06 Journal: Expert review of anti-infective therapy [Category] COVID19(2023년), [키워드] COVID-19 daclatasvir Efficacy Safety sofosbuvir [DOI] 10.1080/14787210.2021.1950532 [Article Type] Randomized Controlled Trial
The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silicoSARS-CoV-2 RNA 의존성 RNA 중합효소에 대한 항-HCV, Sofosbuvir 대 항-EBOV Remdesivir in silicoArticle Published on 2022-02-012022-09-11 Journal: Molecular diversity [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] active form affecting Anti-HCV antiviral drugs approved binding binding affinity binding energy binding mechanism clinically comparable complexes Control coronavirus diseases Coronaviruses COVID-19 disease docked docking drug Drug repurposing Effectiveness Efficacy FDA HCV Health help in silico inhibitor Interaction Ligand limit molecular docking molecular dynamics Molecular dynamics simulation Nsp12 nsp12 protein nucleotide polymerases positive control Protein RdRP Remdesivir reported RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 RdRp SARS-CoV-2 RNA sofosbuvir target tested the binding affinity the SARS-CoV-2 therapeutic target three-dimensional structure used to evaluate Viral protein [DOI] 10.1007/s11030-020-10178-z PMC 바로가기 [Article Type] Article
Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trialsCOVID-19에 대한 항 바이러스 요법의 효능 : 무작위 대조 시험의 체계적인 검토Research Published on 2022-01-312022-09-10 Journal: BMC Infectious Diseases [Category] SARS, 임상, 치료제, [키워드] Administered Antiviral antiviral therapy Antiviral treatment approved article Clinical improvement clinical outcomes controlled trials coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 mortality COVID-19 patients COVID-19 treatment daclatasvir demonstrated Descriptive statistics disease course effective Efficacy Evidence examined exhibited guideline heterogeneity identify improve clinical outcome include inferential statistics network not performed patients performed public health randomized clinical trial randomized clinical trials Randomized controlled trial Randomized controlled trials RCT reducing reducing mortality Remdesivir Result retrieved SARS-CoV-2 Scottish sofosbuvir sofosbuvir/daclatasvir Statistical power study heterogeneity suggested supplementary material systematic literature search systematic review the disease therapeutic Time to recovery Treatment trials was performed were excluded were expressed [DOI] 10.1186/s12879-022-07068-0 PMC 바로가기 [Article Type] Research
Antivirals for adult patients hospitalized with SARS-CoV-2 infection: A randomized, Phase II/III, multicenter, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn: protocol and statistical analysis planSARS-CoV-2 감염으로 입원한 성인 환자를 위한 항바이러스제: 다중 병기와 단계를 포함하는 무작위, II/III상, 다기관, 위약 대조, 적응 연구. COALITION COVID-19 BRAZIL IX - 혁명: 프로토콜 및 통계 분석 계획Article Published on 2022-01-012022-09-11 Journal: Revista Brasileira de Terapia Intensiva [Category] SARS, 임상, 치료제, [키워드] adaptive antiviral drugs Arm Atazanavir Combination COVID-19 daclatasvir decrease described drug effective emerging disease English Evidence expected Hepatitis hepatitis C hepatitis C virus HIV Hospitalized identify initiated Intervention maintain medication multicenter Neste oxygen pacientes com COVID-19 para participant Participants Patient patients hospitalized patients with COVID-19 pelo phase Placebo placebo-controlled Population protocol randomizado Randomized rationale reduce Repurposed drugs Respiratory Support revolution room air SARS-CoV-2 sofosbuvir SpO2 Stage stages Statistical analysis plan status supplemental oxygen Symptom tested the SARS-CoV-2 total sample size Trial Viral load [DOI] 10.5935/0103-507X.20220002-pt PMC 바로가기 [Article Type] Article
Recapitulating Trafficking of Nucleosides Into the Active Site of Polymerases of RNA Viruses: The Challenge and the PrizeMedical Technology Published on 2021-12-142022-11-01 Journal: Frontiers in Medical Technology [Category] COVID-19, [키워드] antiviral agent approach approved cause cellular challenge classical Compound computational approach coronavirus COVID-19 pandemic curative treatment described docking early stage effective Flaviviridae HCV Hepatitis hepatitis C virus hepatitis C virus (HCV) human pathogen inhibitor metabolite molecular dynamics simulations NS5B Nsp12 NTP nucleoside nucleoside analog nucleoside analog drugs nucleotide polymerase Prize protocol RdRP RdRps RNA RNA virus RNA-dependent RNA polymerase SARS-CoV-2 Site sofosbuvir Still therapy viral infections viruses Zika [DOI] 10.3389/fmedt.2021.705875 PMC 바로가기 [Article Type] Medical Technology
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trialCOVID-19 환자에서 소포스부비르와 다클라타스비르 또는 라비다스비르의 효능 및 안전성: 무작위 대조 시험Clinical Trial Published on 2021-12-012022-09-11 Journal: Journal of medical virology [Category] 신약개발, 임상, 치료제, [키워드] added addition Admission Antiviral antiviral drugs Antiviral treatment approved ARMS clinical impact coronavirus coronavirus disease COVID-19 COVID-19 infection COVID-19 infections daclatasvir Day DCV Deterioration distress effective therapy Efficacy Efficacy and safety eligible patient endpoints evaluate Evidence evidence of Fever headache ICU ICU admission identify improvement incidence infections intensive care intensive care unit mechanical ventilation moderate moderate to severe Mortality negativity no evidence of Open-label open-label trial oxygen oxygen saturation Patient patients with moderate positive Randomized Randomized controlled trial ravidasvir RDV repurposing repurposing antiviral drugs respiratory distress Severe COVID-19 Infection severe COVID-19 infections significantly significantly lower sofosbuvir sofosbuvir plus daclatasvir standard care Standard of care Support Symptom Treatment Trial [DOI] 10.1002/jmv.27264 PMC 바로가기 [Article Type] Clinical Trial